Sarah Eliuth Ochoa Hugo | Nanomedicine | Young Scientist Award

Dr. Sarah Eliuth Ochoa Hugo | Nanomedicine | Young Scientist Award

Dr. Sarah Eliuth Ochoa Hugo at Center of Research and Assistance in Technology and Design of the State of Jalisco| Mexico

Dr. Sarah Eliuth Ochoa Hugo is a dedicated pharmaceutical chemist, biotechnologist, and researcher specializing in medical and pharmaceutical innovation. Currently pursuing her Ph.D. in Biotechnological Innovation Applied to Health at CIATEJ, she integrates her expertise in biotechnology, nanotechnology, and pharmacology to address critical challenges in cancer, Alzheimer’s disease, and medical device safety. As a lecturer at Universidad del Valle de México, she mentors future health professionals, guiding them in scientific research and publication. Alongside academia, she engages in entrepreneurial initiatives that merge scientific innovation with social impact, demonstrating her commitment to advancing healthcare through research, education, and applied technology.

Publication Profile 

Orcid

Education 

Dr. Sarah Eliuth Ochoa Hugo is currently a Ph.D. candidate in Biotechnological Innovation Applied to Health at CIATEJ, focusing on advanced biomedical solutions. She previously earned her Master of Science in Biotechnological Innovation Applied to Medical and Pharmaceutical Sciences at CIATEJ, where her thesis explored exosomal cargo in Alzheimer’s pathogenesis. Her academic foundation was built at Universidad del Valle de México, where she completed a Bachelor of Science in Pharmaceutical Chemistry and Biotechnology. There, she validated a 3D glioblastoma multiforme culture model. Complementing her degrees, she has completed certifications in pharmaceutical regulation, medical English, cancer biology, pharmacology, and advanced English proficiency.

Experience 

Dr. Sarah Eliuth Ochoa Hugo serves as an undergraduate lecturer in Health Sciences at Universidad del Valle de México, where she promotes research-oriented learning and student publications. She is co-founder of Quality Approvers, a startup advancing process optimization using Lean and Six Sigma methodologies. Previously, she worked as a Pharmaceutical Chemist and Assistant Sanitary Responsible at San Javier Hospital, ensuring pharmaceutical compliance and safety. During the pandemic, she launched Paihuenk, a social entrepreneurship project producing artisanal cosmetics to support local communities. With extensive academic and industry experience, she bridges biomedical research, pharmaceutical practice, and innovation-driven entrepreneurship in health and biotechnology.

Awards and Honors 

Dr. Sarah Eliuth Ochoa Hugo achievements are reflected through her strong academic and research portfolio, including international presentations at the Society for Neuroscience meetings in San Diego and publications in prominent journals. Her certification by COFEPRIS in pharmaceutical dispensing underscores her compliance with industry standards, while academic training from King’s College London, Monash University, and Johns Hopkins has expanded her global expertise. At Universidad del Valle de México, she has been recognized for her excellence in teaching, demonstrated. Her contributions to translational research and community-focused entrepreneurship highlight her growing academic influence.

Research Focus 

Dr. Sarah Eliuth Ochoa Hugo research focuses on cancer therapy, Alzheimer’s disease, and medical device vigilance through biotechnological innovation. She has explored 3D glioblastoma culture models, evaluated phenolic compounds for anticancer activity, and investigated exosomal cargo in Alzheimer’s disease. Her recent work integrates nanotechnology, particularly gold nanostructures, for photothermal therapies in colon cancer. Additionally, she contributes to medical device monitoring and pharmaceutical safety through technovigilance research. Her multidisciplinary approach combines molecular biology, pharmacology, and nanomedicine, aiming to design innovative therapies with clinical applications. By integrating biotechnology with applied health sciences, her work advances precision medicine, preventive care, and translational biomedical innovation.

Publication Top Notes

ATSUSHI HOSUI | Oncology Pharmaceuticals | Pharmaceutical Excellence Award

ATSUSHI HOSUI | Oncology Pharmaceuticals | Pharmaceutical Excellence Award

Dr. ATSUSHI HOSUI, Osaka Rosai Hospital, Japan

Dr. Atsushi Hosui, a distinguished hepatologist, earned his M.D. from Osaka University in 1994 🎓. With Japanese Medical License #363021, he holds multiple board certifications in internal medicine, gastroenterology, and hepatology 🏥. Currently serving as Director of Hepatology at Osaka Rosai Hospital, he has led and contributed to numerous clinical trials on NASH, MASH, PBC, and liver cancer 🧬. A member of Japan’s leading medical societies, he is also GCP-trained (2015) 📋. Renowned for his impactful research and over 30 scientific publications, Dr. Hosui is a trailblazer in liver disease therapeutics and pharmaceutical excellence.

Publication Profile 

Scopus

Education

Dr. Atsushi Hosui embarked on his medical journey at the prestigious Osaka University, Japan 🗾, where he earned his Doctor of Medicine (M.D.) degree in March 1994 🎓. Renowned for its excellence in medical education and research, Osaka University provided him with a solid foundation in clinical medicine and scientific inquiry 🧪. His education laid the groundwork for a remarkable career in gastroenterology and hepatology 🏥. Driven by a passion for improving liver health, Dr. Hosui has since become a respected physician, researcher, and clinical investigator, dedicated to advancing pharmaceutical science and patient care globally.

Awards

Dr. Atsushi Hosui holds a prestigious Japanese Medical License (#363021) 🇯🇵, validating his long-standing commitment to clinical excellence. He is a board-certified member and specialist of the Japanese Society of Internal Medicine 🧬, where he also serves as an advising doctor 👨‍⚕️. His specialization extends to gastroenterology and hepatology, holding certified status from the Japanese Society of Gastroenterology 🏥, the Japan Society of Hepatology 🏆, and the Japan Gastroenterological Endoscopy Society 🔬. These recognitions underscore his expertise in digestive health and liver diseases, reflecting a distinguished career devoted to patient care and research innovation.

Experience

Dr. Atsushi Hosui has led and contributed to numerous groundbreaking clinical research projects in hepatology and internal medicine 🧬. As an investigator or sub-investigator, he played key roles in studies on NASH (2021–2022) and MASH (2024–2025) 🩺. His focus on hypozincemia (2015), hepatocellular carcinoma (2012–2016), portal vein thrombosis (2015–2016), and PBC (2025–) highlights his expertise in liver-related conditions 🧠. He also contributed significantly to studies on thrombocytopenia and chronic hepatitis C (2013) 🧫. Dr. Hosui’s research dedication reflects his mission to improve liver health and advance pharmaceutical excellence globally.

Research Focus

Dr. Atsushi Hosui’s research is centered around hepatology and gastroenterology, with a strong emphasis on hepatocellular carcinoma (HCC) 🧫, chronic liver diseases 🏥, and vascular complications like gastric varices and Budd-Chiari syndrome 🫀. His clinical investigations span topics such as portal hypertension, black esophagus, hyperglycemic complications, and the long-term risks of hepatitis B treatments 🦠. His innovative approaches combine locoregional therapies, embolization techniques, and pharmacologic interventions to enhance liver cancer outcomes 🎯. Dr. Hosui’s work bridges diagnostic precision with therapeutic advancements in liver-related pathologies, reinforcing his role as a leader in hepatic disease management.

Publication Top Notes

  • Management of Gastric Varices with Portopulmonary Venous Anastomosis: A Combined Approach Using Percutaneous Transhepatic Coil Embolization and Balloon-Occluded Retrograde Transvenous Obliteration
  • Efficacy of Adding Locoregional Therapy in ATZ/BEV-Treated Patients with Stable HCC
  • Black Esophagus in Hyperosmolar Hyperglycemic Syndrome
  • The Risk of Developing Hepatocellular Carcinoma Persists in Chronic Hepatitis B Patients Even After the Long-Term Administration of Nucleos(t)ide Analogs
  • Solitary Cardiac Metastasis of Hepatocellular Carcinoma
  • Hepatocellular Carcinoma Associated with Secondary Budd-Chiari Syndrome